NCT04776655 2025-10-02
LIBImAb
Azienda USL Reggio Emilia - IRCCS
Phase 3 Recruiting
Clinical Trials
5 trialsNCT06293014 2024-03-05
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer
Henan Cancer Hospital
Phase 2 Recruiting
NCT05314101 2022-08-23
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT03380689 2021-03-08
SIRB2
Fujian Cancer Hospital
Phase 1 Withdrawn
NCT01249521 2010-11-30
Vengeance
Austin Health
Phase 2 Unknown